Skip to main content
. 2019 Jul 25;4(14):e127474. doi: 10.1172/jci.insight.127474

Figure 6. Antitumor effects by PS DNA oligo–modified pY(418)-Src antibody.

Figure 6

(A) Tumor growth kinetics when treated with indicated modified antibodies (n = 8). SD shown. Two-way ANOVA (Tukey’s multiple-comparisons test) was used: ***P < 0.001. (B) ELISA on pY(418)-Src recognition by anti-pY(418)Src antibody upon modification performed twice in triplicates. (C) Representative Western blot assessing gene expression in tissue homogenates isolated from tumors. (D) Tumor tissue integrity, tumor accumulation of modified antibodies and CD31+ tumor vasculature, and pY(418)-Src levels shown by confocal microscopy (left) with quantification (right). (E) Representative RT-PCR on Src kinase target gene mRNA expression in tumors treated as indicated, performed in triplicates. (B, D, and E) SD shown. Unpaired Student’s t test: **P < 0.01, and ***P < 0.001.